Back to Search Start Over

Current Landscape and Future Directions of Biomarkers for Immunotherapy in Hepatocellular Carcinoma

Authors :
Vittorio Cristini
Michael A. Curran
Eugene J. Koay
Yehia I. Mohamed
Betul Gok Yavuz
Elshad Hasanov
Sunyoung S. Lee
Ahmed Kaseb
Source :
Journal of Hepatocellular Carcinoma
Publication Year :
2021
Publisher :
Dove, 2021.

Abstract

Hepatocellular carcinoma (HCC) is the most common liver cancer and one of the leading causes of cancer-related deaths in the world. Multiple immunotherapeutic approaches have been investigated to date, and immunotherapy has become the new standard of care therapy in HCC. However, the current role of immunotherapy in HCC remains non-curative. Given this context, a high priority for oncology is understanding the biomarkers that predict clinical response to immunotherapy, have the potential to improve patient selection to maximize the clinical benefit, and spare unnecessary toxicity. In this review, we summarize the key predictive and prognostic biomarkers investigated in immunotherapy clinical trials in HCC and the emerging biomarkers to serve as a roadmap for future clinical trials. Biomarkers from tumoral tissues including PDL-1 expression, tissue infiltrating lymphocytes, tumor mutational burden (TMB) and specific immune signatures, and from peripheral blood including neutrophil-to-lymphocytes ratio, platelet-to-lymphocytes ratio, circulating tumor DNA (ctDNA), circulating tumor cells (CTCs), and specific cytokines, along with gut microbiota are among the studied biomarkers to date in the HCC era. More integrative approaches, including mathematical biomarkers to predict immunotherapy outcomes, are yet to be studied in HCC.

Details

Language :
English
ISSN :
22535969
Volume :
8
Database :
OpenAIRE
Journal :
Journal of Hepatocellular Carcinoma
Accession number :
edsair.doi.dedup.....c532238b8731fd6d2c19b53e1248feaf